Page 58 - ப்ரிஸ்க்ரிப்ஶந் மருந்து பயனர் கட்டணம் நாடகம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

BioMarin Completes Full Enrollment in Phase 2 Study of Vosoritide for Treatment of Infants and Young Children with Achondroplasia Topline data expected to be available in mid-2022 News provided by Share this article Share this article SAN RAFAEL, Calif., March 3, 2021 /PRNewswire/  BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that the company has completed full enrollment in a global Phase 2 randomized, placebo-controlled study of vosoritide, an investigational, once daily injection analog of C-type Natriuretic Peptide (CNP) for children with achondroplasia, the most common form of disproportionate short stature in humans. The 52-week study consists of approximately 70 infants and young children with achondroplasia, aged zero to less than five years old (60 months). The study will be followed by a subsequent open-label extension trial where all children receive active treatment. Children in this study will have completed a minimum three- or six-month baseline st

United statesHank fuchsMunira shamimAsia pacificJohna phillipsDebra charlesworthTraci mccartyCompany securitiesEuropean commissionDrug administrationBiomarin pharmaceutical incPediatric advisory committeeExchange commissionWorldwide researchMetabolic drugs advisory committeeEuropean medicines agency